Landmark NAD3 human study shows improvements in cellular NAD+ status and biomarkers of cardiovascular health – PR Web

CARLSBAD, Calif. (PRWEB) May 05, 2022

NAD3 is a multi-patents-pending nutraceutical containing a unique Wasabi Japonica extract, Theacrine and Copper(I)-Niacin complex. Preliminary pre-clinical and human studies suggest that NAD3 upregulates enzymes that boost the conversion of NAD+ precursors, such as niacin, niacinamide, nicotinamide riboside (NR) and/or NMN to NAD+, while also suppressing the activity of proteins that deplete and consume NAD+. Collectively, these data support the use of NAD3 in combination with any NAD+ precursor or booster (as an ideal companion) for amplifying net cellular NAD+ status.

Recently published in the prestigious journal Physiologia, human data from the ENHANCE Trial revealed that 12 weeks of oral supplementation with NAD3 decreased various independent cardiovascular risk factors (e.g., VLDL, TAGs, LDL-C and Total Cholesterol) by 16% to 19%. In the same study, beneficial changes in the NAD+/NADH ratio were noted despite the fact that NAD3 does NOT contain an appreciable dose of an NAD vitamin precursor. Taken together, the data provide a strong basis for including NAD3 as part of a comprehensive plan to optimize cardiometabolic health and longevity.

While its still the "early days" for NAD3, and much about how NAD+ influences human health and the biology of aging remains to be studied, JUVN3 Holdings continues to invest heavily in NAD3 research. JUVN3 is an ingredient incubator specializing in human longevity. Its NAD3 pipeline of mechanistic, pre-clinical science and human clinical research is well underway. They are committed to providing a solid body of clinical evidence that pushes the forefront of science, advances the field of longevity, and makes a positive impact on human healthspan for society.

While previous studies have demonstrated increases in NAD+ levels using supplement precursors (e.g. niacin, niacinamide, nicotinamide riboside (NR), NMN), NAD3 is the first nutraceutical to demonstrate an improvement in NAD+ status without utilizing a precursor. Its also the first NAD ingredient to show clinical benefits in humans.

NAD3 is distributed exclusively by Compound Solutions, Inc. (CSI) on behalf of JUVN3. Compound Solutions is the go-to company representing and distributing unique, patented nutraceutical ingredients that improve the health and performance of individuals. CSI supplies effective, science-based ingredients to wellness brands, sports nutrition, functional food and nutraceutical manufacturers. CSI is committed to building and maintaining long-term relationships with our global customers and suppliers.

*ENHANCE Trial: Effects of NAD3 on Hallmarks of Aging and Clinical Endpoints of Health in Middle Aged Adults: a subset analysis focused on blood cell NAD+ concentrations and lipid metabolism.

Share article on social media or email:

More here:
Landmark NAD3 human study shows improvements in cellular NAD+ status and biomarkers of cardiovascular health - PR Web